PHARMACOTHERAPY OF ALCOHOLISM: GAPS IN KNOWLEDGE AND OPPORTUNITIES FOR RESEARCH
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
During the past decade, renewed interest in medications to prevent relapse in alcoholics has yielded a number of promising candidates. Although two of these medications, naltrexone and acamprosate, are currently in clinical use in a number of countries, overall, their effectiveness appears to be limited. Disulfiram, the deterrent medication that was approved 50 years ago for the treatment of alcoholism, has not consistently been shown to be efficacious. However, since inadequate dosing and other modifiable factors may limit its deterrent effects, the identification of a more potent metabolite of disulfiram appears to warrant further evaluation. Studies of serotonergic agonists for treatment of alcoholism have also yielded inconsistent results. There is evidence, however, that subgroups of alcoholics may respond well to such medications, suggesting that treatment matching may enhance their efficacy. In addition, nalmefene, a compound with effects similar to naltrexone, as well as a sustained release formulation of naltrexone, may enhance the beneficial effects of opioid antagonist therapy. Despite these developments, much remains to be learned about the pharmacotherapy of alcoholism. The ongoing development and evaluation of novel medications should be given a high priority. However, such basic issues as the optimal dosing strategy and duration of treatment for existing therapies are not known. Similarly, combination therapy, involving either multiple medications or the combination of medication with specific psychotherapies, has not been well studied. The utility of specific pharmacotherapies in women, different ethnic/racial groups, adolescent and geriatric patients, and individuals with co-morbid alcohol and drug use disorders (including nicotine dependence) is also largely unknown, as is the appropriateness of medication therapy for treatment of early problem drinkers. The ultimate aim of these efforts is the development of algorithms for the pharmacological treatment of heavy drinking, which incorporate the characteristics of the patient and of pharmacological and psychosocial treatments with demonstrated efficacy. Although a general framework for such an effort currently exists, much detail is needed before it will be of widespread clinical value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830160031005 · Cited by 2,085
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Alcoholism treatment by disulfiram and community reinforcement therapy
Azrin, N. H., Sisson, R. W., Meyers, R., & Godley, M. (1982) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/0005-7916(82)90050-7 · Cited by 411 · cited 1×
“Azrin et al. (1982) found that a trial programme of stimulus control training, role playing, communication skills training and recreational and vocational counselling improved outcome in disulfiram-treated patients compared with those receiving placebo.”
ResultEffect of naltrexone on alcohol “high” in alcoholics
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.613 · Cited by 308
A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence
Mason, B. J., Salvato, F. R., Williams, L. D., Ritvo, E. C., & Cutler, R. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.8.719 · Cited by 271
Naltrexone-induced alterations in human ethanol intoxication
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1463 · Cited by 254 · cited 2×
“In a laboratory study of non-problem drinkers, naltrexone was found to reduce the reinforcing (i.e. stimulant) effects and increase the unpleasant (i.e. sedative) properties of initial alcohol consumption (Swift et al., 1994).”
Background
Cited by
Room, R., Babor, T., & Rehm, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17870-2 · Cited by 1,625
depue, R. A., & morrone-strupinsky, J. V. (2005) · Behavioral and Brain Sciences · doi:10.1017/s0140525x05000063 · Cited by 958
Addolorato, G. (2002) · Alcohol and Alcoholism · doi:10.1093/alcalc/37.5.504 · Cited by 481
Kiefer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., Kämpf, P., Stracke, R., Baehr, M., Naber, D., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.92 · Cited by 400
Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐Analysis
Kranzler, H. R., & Van Kirk, J. (2001) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2001.tb02356.x · Cited by 390
Self-citation
Metadata
- Authors
- Kranzler, H. R.
- Venue
- Alcohol and Alcoholism
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-11-01
- Volume
- 35
- Issue
- 6
- Pages
- 537-547
- ISSN
- 0735-0414 (ISSN-L)
- 1464-3502
- OpenAlex
- W2118994821
- Cited by
- 106
- References
- 6
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.